Search over 3,000 reports

    Narcolepsy- Market Insights, Epidemiology and Market Forecast-2023

    Narcolepsy- Market Insights, Epidemiology and Market Forecast-2023
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 99
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0005
    DelveInsight's "Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Narcolepsy for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 2013-2023.
    Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations.
    Narcolepsy affects approximately 200,000 Americans and 3 million people worldwide. Narcolepsy is not rare, but it is severely under-recognized and commonly misdiagnosed. Narcolepsy appears throughout the world but occurrence rates vary among populations. The occurrence rate of narcolepsy is remarkably lower in Israel and quite higher in Japan compared to the United States. In Europe, the occurrence rate is found to be higher in UK and Germany than other European countries.
    PROVIGIL by Cephalon, Inc and XYREM by Jazz Pharmaceuticals is the top selling drug for Narcolepsy contributing to majority of the market share. Other drugs are also being used for the treatment of Narcolepsy as secondary indication, but do not have much impact on the overall market size. We have estimated that the worldwide Narcolepsy will increase at a CAGR of 8.48% during the forecast period 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Scope
    - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
    - Marketed information including available prescription drugs, its patent and exclusivity details.
    - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
    - It also provides Market size of Narcolepsy for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
    Report Introduction
    Narcolepsy Market Overview at a Glance
    Market Size of Narcolepsy in 7MM, 2017
    Market Size of Narcolepsy in 7MM, 2023
    Narcolepsy
    Overview
    Signs and Symptoms
    Complications
    Pathophysiology
    Etiology
    Risk Factors
    Diagnosis
    Treatment
    Lifestyle adjustments
    Behavioural
    Epidemiology of Narcolepsy in 7MM
    United States
    Prevalent Population of Narcolepsy in United States
    Narcolepsy cases with and without Cataplexy in United States
    Europe
    United Kingdom
    Prevalent Population of Narcolepsy in United Kingdom
    Narcolepsy cases with and without Cataplexy in United Kingdom
    Germany
    Prevalent Population of Narcolepsy in Germany
    Narcolepsy cases with and without Cataplexy in Germany
    France
    Prevalent Population of Narcolepsy in France
    Narcolepsy cases with and without Cataplexy in France
    Italy
    Prevalent Population of Narcolepsy in Italy
    Narcolepsy cases with and without Cataplexy in Italy
    Spain
    Prevalent Population of Narcolepsy in Spain
    Narcolepsy cases with and without Cataplexy in Spain
    Japan
    Prevalent Population of Narcolepsy in Japan
    Narcolepsy cases with and without Cataplexy in Japan
    Treatment Algorithm
    Current Unmet Needs
    Marketed (FDA / EMA Approved) Drugs
    PROVIGIL
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    XYREM
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Other Drugs
    Anafranil (clomipramine)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Desipramine
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Prozac (Fluoxetine)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Tofranil (Imipramine)
    Description
    Advantages and Disadvantages
    Product Profile
    Vivactil (Protriptyline)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Zoloft (Sertraline)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Effexor (Venlafaxine)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Desoxyn (Methamphetamine)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    NUVIGIL
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Wakix (Pitolisant)
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Ritalin
    Description
    Regulatory Milestones:
    Advantages and Disadvantages
    Product Profile
    Dexedrine
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Adderall
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Atomoxetine
    Description
    Regulatory Milestones
    Advantages and Disadvantages
    Product Profile
    Emerging Therapies
    NLS-1/NLS-0: NLS Pharma
    Description
    Regulatory Milestones
    Clinical Development
    JZP-258: Jazz Pharmaceuticals Inc
    Description
    Regulatory Milestones
    Clinical Development
    Clinical Trial by Phase
    JZP-110: Jazz Pharmaceuticals
    Description
    Regulatory Milestones
    Clinical Development
    Product Profile
    Clinical Trial by Phase
    FT218: Avadel Pharmaceuticals
    Description
    Regulatory Milestones
    Clinical Development
    Product Profile
    Clinical Trial by Phase
    Global Narcolepsy: Country-Wise Market Analysis
    Total Market Size of Narcolepsy (2013-2023)
    United States
    EU5
    United Kingdom
    Germany
    France
    Italy
    Spain
    Japan
    Market Drivers
    Market Barriers
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Prevalent, Diagnosed and Treatable Cases of Narcolepsy in United States (2013-2023)
    Table 2: Narcolepsy with and without Cataplexy cases in United States (2013-2023)
    Table 3: Prevalent, Diagnosed and Treatable cases of Narcolepsy in United Kingdom (2013-2023)
    Table 4: Narcolepsy with and without Cataplexy cases in United Kingdom (2013-2023)
    Table 5: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Germany (2013-2023)
    Table 6: Narcolepsy with and without Cataplexy cases in Germany (2013-2023)
    Table 7: Prevalent, Diagnosed and Treatable cases of Narcolepsy in France (2013-2023)
    Table 8: Narcolepsy with and without Cataplexy cases in France (2013-2023)
    Table 9: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Italy (2013-2023)
    Table 10: Narcolepsy with and without Cataplexy cases in Italy (2013-2023)
    Table 11: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Spain (2013-2023)
    Table 12: Narcolepsy with and without Cataplexy cases in Spain (2013-2023)
    Table 13: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Japan (2013-2023)
    Table 14: Narcolepsy with and without Cataplexy cases in Japan (2013-2023)
    Table 15: Total Market size of Narcolepsy in USD Millions (2013-2023)
    Table 16: United States Market Size of Narcolepsy in USD Million (2013-2023)
    Table 17: United Kingdom Market Size of Narcolepsy in USD Million (2013-2023)
    Table 18: Germany Market Size of Narcolepsy in USD Million (2013-2023)
    Table 19: France Market Size of Narcolepsy in USD Million (2013-2023)
    Table 20: Italy Market Size of Narcolepsy in USD Million (2013-2023)
    Table 21: Spain Market Size of Narcolepsy in USD Million (2013-2023)
    Table 22: Japan Market Size of Narcolepsy in USD Million (2013-2023)
    Figure 1: 2017 7MM Market Scenario
    Figure 2: 2023 7MM Market Scenario
    Figure 3: Prevalent Population of Narcolepsy in United States (2013-2023)
    Figure 4: Prevalent, Diagnosed and Treatable cases of Narcolepsy in United States (2013-2023)
    Figure 5: Narcolepsy with and without Cataplexy cases in United States (2013-2023)
    Figure 6: Prevalent Population of Narcolepsy in United Kingdom (2013-2023)
    Figure 7: Prevalent, Diagnosed and Treatable cases of Narcolepsy in United Kingdom (2013-2023)
    Figure 8: Narcolepsy with and without Cataplexy cases in United Kingdom (2013-2023)
    Figure 9: Prevalent Population of Narcolepsy in Germany (2013-2023)
    Figure 10: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Germany (2013-2023)
    Figure 11: Narcolepsy with and without Cataplexy cases in Germany (2013-2023)
    Figure 12: Prevalent Population of Narcolepsy in France (2013-2023)
    Figure 13: Prevalent, Diagnosed and Treatable cases of Narcolepsy in France (2013-2023)
    Figure 14: Narcolepsy with and without Cataplexy cases in France (2013-2023)
    Figure 15: Prevalent Population of Narcolepsy in Italy (2013-2023)
    Figure 16: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Italy (2013-2023)
    Figure 17: Narcolepsy with and without Cataplexy cases in Italy (2013-2023)
    Figure 18: Prevalent Population of Narcolepsy in Spain (2013-2023)
    Figure 19: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Spain (2013-2023)
    Figure 20: Narcolepsy with and without Cataplexy cases in Spain (2013-2023)
    Figure 21: Prevalent Population of Narcolepsy in Japan (2013-2023)
    Figure 22: Prevalent, Diagnosed and Treatable cases of Narcolepsy in Japan (2013-2023)
    Figure 23: Narcolepsy with and without Cataplexy cases in Japan (2013-2023)
    Figure 24: Treatment Algorithm, 2017
    Figure 25: Current Unmet Needs of Narcolepsy
    Figure 26: Total Market Size of Narcolepsy in USD Millions (2013-2023)
    Figure 29: United States Market Size of Narcolepsy in USD Millions (2013-2023)
    Figure 30: United Kingdom Market Size of Narcolepsy in USD Million (2013-2023)
    Figure 31: Germany Market Size of Narcolepsy in USD Million (2013-2023)
    Figure 32: France Market Size of Narcolepsy in USD Million (2013-2023)
    Figure 33: Italy Market Size of Narcolepsy in USD Million (2013-2023)
    Figure 34: Spain Market Size of Narcolepsy in USD Million (2013-2023)
    Figure 35:Japan Market Size of Narcolepsy in USD Million (2013-2023)
    Narcolepsy Market (7MM)

    NarcolepsyMarket forecasting

    Narcolepsy Sales forecasting

    Narcolepsy Market segments

    Narcolepsy Epidemiology

    Narcolepsy Pipeline products and technologies

    Narcolepsy Competitive landscape

    Narcolepsy SWOT analysis

    Narcolepsy Market Driver's and barriers

    Narcolepsy Key Companies and Funding

    • Single User License
      (20% Off)
      $4,950.00
      $3960
    • Site License
      (30% Off)
      $9,900.00
      $6930
    • Global License
      (40% Off)
      $14,850.00
      $8910

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap